Stefanie Srock

1.6k total citations
21 papers, 1.1k citations indexed

About

Stefanie Srock is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Stefanie Srock has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Stefanie Srock's work include Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Stefanie Srock is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Stefanie Srock collaborates with scholars based in Germany, Switzerland and France. Stefanie Srock's co-authors include Michael Herold, Robert Rohrberg, Herbert I. Hurwitz, Sabine Neser, Gottfried Dölken, Antje Haas, Andreas Neubauer, K. Höffken, Mathias Freund and Wolfgang Knauf and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Stefanie Srock

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefanie Srock Germany	12	787	506	302	246	154	21	1.1k
David Belada Czechia	18	604 0.8×	819 1.6×	124 0.4×	327 1.3×	55 0.4×	167	1.1k
Sylvain Mareschal France	19	390 0.5×	787 1.6×	187 0.6×	263 1.1×	271 1.8×	34	1.1k
Margaret Shovlin United States	13	639 0.8×	991 2.0×	134 0.4×	374 1.5×	262 1.7×	28	1.3k
Fabrizio Tabbò Italy	17	560 0.7×	431 0.9×	413 1.4×	159 0.6×	265 1.7×	51	1.2k
Carsten Hirt Germany	18	449 0.6×	774 1.5×	163 0.5×	433 1.8×	70 0.5×	42	1.1k
F. Morschhauser France	13	449 0.6×	693 1.4×	123 0.4×	182 0.7×	52 0.3×	27	944
Hui-Qiang Huang China	22	819 1.0×	740 1.5×	139 0.5×	151 0.6×	114 0.7×	51	1.4k
Roswitha Forstpointner Germany	15	1.1k 1.4×	1.5k 2.9×	235 0.8×	732 3.0×	67 0.4×	38	1.7k
John H. Barton United States	15	526 0.7×	350 0.7×	284 0.9×	244 1.0×	67 0.4×	32	885

Countries citing papers authored by Stefanie Srock

Since Specialization

Citations

This map shows the geographic impact of Stefanie Srock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefanie Srock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefanie Srock more than expected).

Fields of papers citing papers by Stefanie Srock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefanie Srock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefanie Srock. The network helps show where Stefanie Srock may publish in the future.

Co-authorship network of co-authors of Stefanie Srock

This figure shows the co-authorship network connecting the top 25 collaborators of Stefanie Srock. A scholar is included among the top collaborators of Stefanie Srock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefanie Srock. Stefanie Srock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnston, Stephen, Anna Emde, Carlos H. Barrios, et al.. (2023). Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences. JNCI Cancer Spectrum. 7(4). 7 indexed citations

Grothey, Axel, Josep Tabernero, Dirk Arnold, et al.. (2018). Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Annals of Oncology. 29. viii714–viii715. 75 indexed citations

Loupakis, Fotios, Herbert I. Hurwitz, Leonard B. Saltz, et al.. (2018). Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer. 119(12). 1451–1455. 14 indexed citations

Siena, Salvatore, Andrea Sartore‐Bianchi, Silvia Marsoni, et al.. (2018). Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology. 29(5). 1108–1119. 173 indexed citations

Loupakis, Fotios, Herbert I. Hurwitz, Leonard B. Saltz, et al.. (2018). Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 36(4_suppl). 726–726. 4 indexed citations

Ilhan‐Mutlu, Aysegül, Matthias Osswald, Yunxiang Liao, et al.. (2016). Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. Molecular Cancer Therapeutics. 15(4). 702–710. 86 indexed citations

Llombart‐Cussac, Antonio, Xavier Pivot, Laura Biganzoli, et al.. (2014). A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. The Breast. 23(5). 656–662. 35 indexed citations

Gligorov, Joseph, Dinesh Doval, José Bines, et al.. (2014). Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. The Lancet Oncology. 15(12). 1351–1360. 96 indexed citations

Minckwitz, Gϋnter von, Fabio Puglisi, Javier Cortés, et al.. (2014). Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. The Lancet Oncology. 15(11). 1269–1278. 100 indexed citations

10.

Robert, Nicholas J., Véronique Dièras, Christian Jackisch, et al.. (2014). Abstract CT322: Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research. 74(19_Supplement). CT322–CT322. 1 indexed citations

11.

Gligorov, Joseph, D.C. Doval, José Bines, et al.. (2014). Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer (Mbc): Imelda Randomised Phase III Trial. Annals of Oncology. 25. iv116–iv116. 2 indexed citations

12.

Llombart‐Cussac, Antonio, Xavier Pivot, Laura Biganzoli, et al.. (2013). A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.. Journal of Clinical Oncology. 31(15_suppl). 555–555. 4 indexed citations

13.

Arnold, Dirk, et al.. (2009). Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany. Journal of Clinical Oncology. 27(15_suppl). e15057–e15057. 2 indexed citations

14.

Hirt, Carsten, Frank Schüler, Thomas Kiefer, et al.. (2008). Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients^†. British Journal of Haematology. 141(5). 631–640. 31 indexed citations

15.

Herold, Michael, Antje Haas, Stefanie Srock, et al.. (2007). Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology. 25(15). 1986–1992. 371 indexed citations

16.

Srock, Stefanie, Folke Schriever, Andreas Neubauer, Michael Herold, & D. Huhn. (2007). Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leukemia & lymphoma. 48(5). 905–911. 8 indexed citations

17.

Srock, Stefanie, et al.. (2005). Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging. 32(10). 1225–1233. 15 indexed citations

18.

Pickartz, Tilman, Alexander Binder, Frauke Ringel, et al.. (2003). Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia. Experimental Hematology. 31(8). 682–685. 7 indexed citations

19.

Potapov, Evgenij, H. R. Zurbrügg, Stefanie Srock, et al.. (2002). Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study. The Annals of Thoracic Surgery. 74(2). 384–389. 21 indexed citations

20.

Pickartz, Tilman, Frauke Ringel, Marianne Wedde, et al.. (2001). Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Experimental Hematology. 29(12). 1410–1416. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact